Setting Specifications AND Stability Testing AND post-conference session Stability Studies

Setting Specifications AND Stability Testing AND post-conference session Stability Studies

Vienna, Austria

Course No 16383


Costs

This Training Course has unfortunately already taken place. However, if you are interested in this seminar, we will be happy to inform you about the new date or about further offers on the topic. Simply use the following contact form to send us your request.

* payable by credit card American Express Visa Mastercard

If you have any questions, please contact us:
Tel.: +49 (0)6221 / 84 44 0 E-Mail: info@gmp-compliance.org

Speakers

Setting Specifications and Acceptance Criteria

Dr Thomas Fürst, SANOFI, Biberach, Germany

Dr Hiltrud Horn, Horn Pharmaceutical Consulting, Germany

Dr Cornelia Nopitsch-Mai, Bonn, Germany

Dr Bettina Pahlen, Quality x Pharma Consulting GmbH, Germany

Dr Thomas Uhlich, Bayer Pharma, Germany


Stability Testing for Drug Substances and Drug Products

Dr Thomas Fürst, SANOFI, Biberach, Germany

Dr Wolfgang Grimm, Germany

Dr Hiltrud Horn, Horn Pharmaceutical Consulting, Germany

Dr Jordi Ruiz-Combalia, Audit GMP, Spain

Dr Thomas Uhlich, Bayer Pharma


Post-Conference Session:

Dr Raphael Bar, BR Consulting, Israel

Programme

Setting Specifications and Acceptance Criteria


Highlights:
  • Regulatory Requirements for Specifications (ICH Q6A)
  • Regulatory Requirements for Specifications of Biotech Products/
  • Well-characterised Biologicals (ICH Q6B, etc.)
  • Principles for Setting of Release and Shelf-life
  • Specifications throughout Development
  • Organic Impurities, Degradation Products and Genotoxic Impurities
  • Rational Development and Justification of API Specifications, Drug Products Specifications, Biological Drug Substances and Products focussing on Monoclonal Antibodies (mAbs)
  • Specifications for Specific Drug Products
  • Specifications for Excipients and Container Closure Systems (EU/US) including important aspects such as latest news on functionality
  • testing (EP, USP) and GMP for excipients

Stability Testing for Drug Substances and Drug Products


Highlights:
  • Stability testing from early development to product launch
  • Stability testing strategies for Drug Products
  • Essential hints for writing the stability part in the CTD
  • Stability Studies after approval (EU/US)
  • Evaluation of stability results – Statistical Considerations

Post-Conference Session Stability Studies to Support Shipping/Distribution of Pharmaceuticals and Biopharmaceuticals


Highlights:
  • Stability programs and stress testing – a regulatory overview
  • Qualification of shipment and temperature monitoring
  • World climatic zones and Mean Kinetic Temperature
  • Storage label statements in the EU and the US
  • Studies at different temperatures and conditions
  • Investigation and evaluation of excursions and responsibility issues

Go back

GMP Conferences by Topics